The file's text, extracted by GovTribe without its formatting.
5. PROJECT NUMBER (if applicable)
CODE
7. ADMINISTERED BY
2. AMENDMENT/MODIFICATION NUMBER
CODE
6. ISSUED BY
8. NAME AND ADDRESS OF CONTRACTOR
4. REQUISITION/PURCHASE REQ. NUMBER
3. EFFECTIVE DATE
9A. AMENDMENT OF SOLICITATION NUMBER
9B. DATED
PAGE OF PAGES
10A. MODIFICATION
OF CONTRACT/ORDER NUMBER
10B. DATED
BPA NO.
1. CONTRACT ID CODE
FACILITY CODE
CODE
Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following methods:
The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers
E. IMPORTANT:
is extended,
(a) By completing Items 8 and 15, and returning __________ copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted; or (c) By separate letter or electronic communication which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR
ACKNOWLEDGMENT TO BE RECEIVED AT
THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY is not extended.
12. ACCOUNTING AND APPROPRIATION DATA
(REV. 11/2016)
is required to sign this document and return ___________ copies to the issuing office is not, A. THIS CHANGE ORDER IS ISSUED PURSUANT TO:
Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.
15C. DATE SIGNED
B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADM
INISTRATIVE CHANGES
SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).
RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by letter or electronic communication, provided each letter or electronic communication makes reference to the solicitation and this amendment, and is received prior to the opening hour and d ate specified.
C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:
D. OTHER
Contractor
16C. DATE SIGNED
14. DESCRIPTION OF AMENDMENT/MODIFICATION
16B. UNITED STATES OF AMERICA
Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.
15A. NAME AND TITLE OF SIGNER
16A. NAME AND TITLE OF CONTRACTING OFFICER
15B. CONTRACTOR/OFFEROR
STANDARD FORM 3
PREVIOUS EDITION NOT USABLE
Prescribed by GSA - FAR (48 CFR) 53.243 (Type or print) (Type or print) (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)
(Number, street, county, State and ZIP Code) (If other than Item 6) (Specify type of modification and authority) (such as changes in paying office, appropriation date, etc.)
(If required)
(SEE ITEM 11)
(SEE ITEM 13)
(X)
CHECK
ONE
13. THIS ITEM APPLIES ONLY TO
MODIFICATIONS OF CONTRACTS/ORDERS,
IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.
11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS
AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT
(Signature of person authorized to sign) (Signature of Contracting Officer) 08-28-2019 687-20-1-020-0007 N/A 36C260 Department of Veterans Affairs Network Contracting Office 20 5115 NE 82nd Ave, Suite 102 Vancouver WA 98662 Y Department of Veterans Affairs Network Contracting Office 20 5115 NE 82nd Ave, Suite 102 Vancouver WA 98662 To all Offerors/Bidders
36C26019Q0597 08-08-2019
X X X ** HOUR & DATE for Receipt of Offers is EXTENDED to: 09/08/2019 The purpose of amendment 0002 to soliciation 36C26019Q0597 is to provide CPT Codes to the attached reference lab test list, to remove FEE laboratory services from the Statement of Work and extend the solicitation close date.
1. Revised test list to include CPT Codes attached to this amendment
2. Revised Statement of Work attached to this amendment
3. Revised close date for this solicitation is extended from 9/1/2019 to 9/8/2019
Jacob Jackson
A.1 STATEMENT OF WORK
STATEMENT OF WORK
Reference Lab Services For the Department of Veterans Affairs Jonathan Wainwright VA Medical Center 77 Wainwright Drive Walla Walla, WA 99362-3975
1. BACKGROUND
The Walla Walla VA Medical Center (VAMC) Laboratory Department requires clinical chemistry and microbiology reference lab services. This full-service reference lab services requirement will provide testing supplies, customer service, courier services, lab result reporting services and verification of certification for test results. This requirement will ensure accurate and timely test results are made available to the Walla Walla VAMC healthcare providers which will ensure high quality healthcare is provided to the Veterans at the Walla Walla VAMC.
2. SCOPE
a. The Reference Laboratory shall provide in accordance with all applicable federal, state, and local regulations, laws, and ordinances, and in accordance with the specifications outlined for accreditation certification if applicable, patient specimen testing for the specific range of referral testing within their capability.
b. Services shall include the performance of analytical testing as defined by the Laboratory's reference test manual, the reporting of analytical test results and consultative services as required assimilating the full scope of its laboratory operations to Walla Walla VA Laboratory Services.
c. All requirements and provisions defined in the specifications of this solicitation will apply to any laboratory, i.e. branch, division, sub-contractor, etc. performing reference testing on behalf of the Reference Laboratory.
d. The VA Facilities will be responsible for specimen collection and will provide laboratory specimens prepared according to the Reference Laboratory's laboratory user’s manual, identified, and labeled for testing.
3. SPECIFIC TASKS
a. Clinical Chemistry:
i. Reference Laboratory shall provide laboratory services to include: preanalytic processing as defined in Reference Laboratory published user’s manual; analysis, reporting of analytic results and interpretation of analytic clinical results. The number of tests requested under this contract will change throughout the life of the contract. The volumes or amounts shown in the solicitation are estimates only and impose no obligation on the VA.
ii. The Reference Laboratory shall also provide the following support services: supplies, customer service, courier service (to include pickup of specimens and transport of specimens to its laboratory), reporting services, and verification of certification.
iii. Provide all necessary supplies as defined in the laboratory user manual, to include, but not limited to the following:
1) Requisition forms or agreed computer ordering system
2) Specimen containers
3) Dry ice and appropriate container
4) Special instructions
5) Log books for samples sent out and results returned
6) Specimen carriers
7) All forms, including Chain of Custody forms
iv. The Reference Laboratory shall provide to the VA Facilities the supplies and equipment within one (1) week of receipt of the delivery order. The VA Facilities will request replenishment of supplies from the Reference Laboratory on an as needed basis via telephone, email or fax. A confirmation of the order shall be supplied to the VA within 24 hours.
v. All supplies shall be shipped FOB Destination.
b. Microbiology:
i. If required the Reference Laboratory shall provide microbiology services for Walla Walla VA Medical Center, Walla Walla, WA. The number of tests requested under this contract will change throughout the life of the contract.
ii. Contractor shall provide laboratory services for Microbiology to include pickup and transport of specimens from the Walla Walla VA to its laboratory; pre-analytic processing as defined in its laboratory user’s manual; analysis, reporting of analytic results, and consultation regarding selection, collection, transportation and result interpretation. The contractor shall provide the following supplies/materials:
1) Special instructions
2) Specimen carriers
3) Special media or tubes for viral samples
4) All supplies for specimen preservation, special tests (e.g., but not limited to, viral studies)
iii. Microbiology preliminary reports shall be provided within 24hrs
4. ELECTRIC INTERFACE
a. If awarded the Reference Laboratory agrees to a transition period for providing a fully functioning interconnection for exchanging data between VISTA, VA Computer system, upcoming EHRM Cerner and the Reference Laboratory's electronic lab information system. During this time the Reference Laboratory will supply the VA Facility with available test menu and agrees to receive test orders as they are transitioned until full menu implementation.
b. System drivers must be compatible with the VA’s Vista Laboratory Electronic Data Exchange (LEDI) software and Cerner. The server and interface software will be owned and maintained by the Reference Laboratory. The Reference Laboratory must have a signed MOU (Memorandum of Understanding) with the VA Network and Security Operations Center (NSOC).
c. This interconnection shall be protected through the use of VA approved encryption algorithms and products as required and in compliance with HIPPA guidelines. Connections at each end shall be located within a controlled access facility. All access shall be controlled by authentication methods to validate approved users.
5. TESTING METHODOLOGY, REFERENCE AND TURN AROUND TIME
a. Routine test results shall be reported within the specified turnaround time (TAT) which is defined from time of specimen pickup to when results are available. TAT is established by the VA facility. In general, majority of Clinical Chemistry should be completed within 1-5 days, see attachment for details. In general, majority of Microbiology should be completed within 2-5 days, see attachment for details. If testing is not within TAT, notify the VA Facilities of the new estimated TAT within 12 hours.
b. Testing methodology and reference ranges for a test must be defined in the Reference Laboratory user manual and/or website. Reference Laboratory shall advise facility of any changes in methodology, procedure, reference ranges and any new tests introduced 30 days in advance.
c. Reference Laboratory agrees to maintain the minimum acceptable service, reporting systems and quality control. Exception handling: Reference Laboratory will notify VA Facilities Laboratory Service within 12 hours of any problems with specimens received.
d. The VA Facilities will provide laboratory specimens prepared according to the Reference Laboratory's user’s manual, identified, and labeled for testing.
e. Routine Microbiology test results shall be reported, preliminary at minimum, within 24 hours (within agreed TAT per each test). STAT test results shall be reported within 2 hours or less of specimen pick-up. Critical Value test results shall be reported immediately. Stat test results will be faxed or telephoned to Laboratory Service. Telephoned results will be confirmed with a follow-up by vendor via fax.
6. CUSTOMER SERVICE
a. The Reference Laboratory will provide VA Laboratory with a means of communication to permit immediate inquiry regarding the status of pending tests or specimen problem, 24 hours per day, 7 days per week.
b. The Reference Laboratory shall provide names and telephone numbers of technical Directors and Pathologists available to provide information.
7. COURIER SERVICES
a. The Reference Lab shall will provide courier services of VA specimens from the Veteran Affairs Community Based Outpatient Clinics (CBOCS) to Jonathan M. Wainwright Memorial Veteran Affairs Medical Center (Walla Walla, WA Laboratory Site) at least daily Monday to Friday, except Federal Holidays, and by request of the Walla Walla Core Lab or the CBOC for training days to transport laboratory specimens.
b. The Reference Laboratory shall be responsible for transporting and storing specimens in such a manner as to ensure stability and integrity of the specimen where applicable. Reference Laboratory shall supply any special preservatives required for specimen preservation.
c. Transport samples in such a manner as to ensure the integrity of the specimen.
d. Reference Laboratory shall supply any special preservatives required for specimen preservation.
e. Reference Laboratory shall notify VA Facilities of any specimen problems or discrepancies from the submitted manifest within 24 hours after shipping.
f. The VA Facilities laboratory manager or designee shall notify the Reference Laboratory during weekends and federal holidays, via telephone, when a pick-up courier is required.
g. The Reference Laboratory shall provide STAT (reportable within two hours or less of specimen pickup) specimen capability.
Community Base Outpatient Clinics:
1. Boardman (tele-medicine clinic), Enterprise (tele-medicine clinic) and La Grande, Oregon to Walla Walla, Washington
2. Lewiston to Walla Walla, Washington
3. Yakima, and Richland, Washington to Walla Walla, Washington
Core Lab and CBOC Addresses:
1. Jonathan M. Wainwright Memorial VA Medical Center 77 Wainwright Dr.
Walla Walla, WA 99362
2. Richland CBOC Federal building 825 Jadwin Avenue, Ste 250 Richland, WA 99352
3. Yakima CBOC 717 Fruitvale Blvd.
Yakima WA 98908
4. La Grande CBOC 202 12th St.
La Grande, OR 97850
5. Lewiston CBOC 1630 23rd Ave Ste 301and 401 Lewiston ID 83501.
6. Boardman Tele-Medicine VA Clinic 2 Marine Dr.
Boardman, Ore 97818
7. Enterprise Tele-Medicine VA Clinic 401 1st Street, Enterprise, Oregon 97828
8. DELIVERY AND REPORTING
a. Billing summaries shall begin the first day of the month and include the last day of the month.
b. Tests referred to another laboratory shall be at no additional transfer charge or confirmation charge to the government.
c. Deliveries must be accompanied by a delivery ticker or sales slip that contains the following information as a minimum:
1) Vendor Name
2) BPA Number, Task order number, and Purchase Order number
3) Date of Purchase
4) Date of Shipment
5) Description of item
6) Quantity of each item
7) Unit price and extended (quantity x unit price) price for each item
d. The Reference Laboratory shall provide a quarterly and end of year report showing sample issues, facility usage, and cost savings generated during the reporting period. The report will be due 45 days after the close of each government fiscal quarter.
e. Yearly antibiogram report to be supplied.
9. PERFORMANCE MONITORING
a. At the time of contract award the Contracting Officer will appoint a Contracting Officer Representative (COR) to assist with the contract monitoring requirements. The COR or designee will monitor such items as quality of service, contractor's ability to meet TAT's, correct billing, customer service, and review of the contractor's proficiency program.
b. Contractor shall provide to the COR or designee no later than Ninety (90) days prior to the end of each contract period a proficiency report. The COR or designee shall review the proficiency results. The contractor shall maintain a minimum of 95% success rate for proficiency testing to be considered successful. Failure to achieve 95% success rate two periods in a row could be grounds for Termination for Cause.
c. The COR or designee will ensure that services performed are in accordance with all terms and conditions of the contract.
d. The delegated COR or designee will notify the Contracting Officer of any non-compliance immediately upon his/her gaining knowledge of any such situation or incident. After such communication, the COR or designee will provide a written statement to the contracting officer along with any supporting documentation regarding the performance failure noted.
e. Upon receipt of a proper invoice, the COR or designee shall certify that the services identified have been performed. Once certification has been made, the invoice will be forward through the proper billing channels and payment shall be made to the Contractor.
f. It is the intention of both parties to conduct joint reviews prior to the expiration date of the contract to determine and evaluate if services being provided are in accordance with the contract terms, payments and billings are being properly handled and to jointly determine if this agreement is satisfactory to both parties in terms of services provided and consideration being received. This review may include. but not be limited to: analyze all billings, payments, costs, administrative issues, patient satisfaction, quality of care and other related documentation that identities that services have been received.
g. Upon conclusion of the initial contract period, and in coordination with the Contracting Officer, the using service shall provide a statement to the Contracting Officer providing a summary of contractor actions and a statement that all requirements of the contract were fulfilled as agreed. This information shall be forwarded by the COR or designee to the Contracting Officer prior to exercising any extension of this agreement (at least 60 days prior to contract expiration).
10. LICENSING AND ACCREDITATION
a. Reference Laboratory shall provide copies of all licenses, permits, accreditation and certificates required by law. Laboratory Director shall be a licensed American Board of Pathology certified pathologist or appropriately certified bio-analyst.
b. All medical facilities providing laboratory services under the contract must possess a valid state license and meet JC standards as well as CLIA requirements and standards of the College of American Pathologists (CAP).
11. PERSONNEL
a. The Reference Laboratory shall make sure employees have current and valid professional certifications before starting work under this contract.
b. The Reference Laboratory staff shall meet personnel qualifications required by Clinical Laboratory Improvement Act (CLIA) '88 Guidelines.
c. The Government’s reserves the right to request information or certification from the contractor verifying they comply with this contract requirement. If discovered the contractor is not in compliance with this requirement the contract shall be terminated for cause in accordance with clause 52.212-4.
d. d. The Reference Laboratory shall provide documentation of completed Courier training with current IATA transport handling regulations.
12. HOURS OF OPERATION
The Walla Walla VA is open Monday thru Friday from 6:30 AM to 5:00 PM and closed on Federal Holidays and may require services during those times.
13. PERIOD OF PERFORMANCE
Contract will be one Base Period plus Four (4) Option Years:
| Base Period: | | 10/1/2019-9/30/2020 |
| Option Year One (1): | 10/1/2020-9/30/2021 | |
| Option Year Two (2): | 10/1/2021-9/30/2022 | |
| Option Year Three (3): | 10/1/2022-9/30/2023 | |
| Option Year Four (4): | 10/1/2023-9/30/2024 | |
14. PATIENT INFORMATION SAFETY
a. The Reference Laboratory shall not use or disclose Protected Health Information (PHI) other than as permitted or required by the agreement or as required by law.
b. The Reference Laboratory shall use appropriate safeguards to prevent use or disclosure of the PHI other than is provided for by this agreement.
c. The Reference Laboratory shall report immediately any breach of safeguards and mitigate any harmful effects related to the use or disclosure of PHI by the Reference Laboratory or any of its agents, including sub-contractors.
15. SECURITY REQUIREMENTS
The Reference Laboratory shall be responsible for adhering to the following statements as they relate to the contract. Walla Walla VA, in coordination with their site Information Security Officer (ISO), shall monitor the work performed by contractor personnel, including sub-contractors, on a periodic basis to make sure contractor personnel are following the stated security requirements.
BACKGROUND INVESTIGATIONS AND SPECIAL AGREEMENT CHECKS
All Reference Laboratory employees are subject to the same level of investigation as VA employees who have access to VA sensitive information. The level of background investigation commensurate with the level of access needed to perform the work is: Low Risk. This requirement is applicable to all subcontractor personnel requiring the same access.
The Reference Laboratory shall bear the expense of obtaining background investigations. If the investigation is conducted by the Office of Personnel Management (OPM) through the VA, the Reference Laboratory shall reimburse the VA within 30 days.
16. DELIVERY SCHEDULE
| SOW Task# |
| Quality Monitor |
| Format |
| Calendar Days After CO Start |
| Acceptability |
Level
| 1 |
| Licensures/Certificates |
| Copies |
| At initial award, and when renewed |
| 100% Received |
| 2 |
| Monthly Test Summary |
| One electronic copy |
| Monthly on the 10th work day |
| 100% Received |
| 3 |
| Contact Phone List |
| One electronic copy |
| At initial award, and when changes occur |
| 100% Received |
| 4 |
| Laboratory User Manual |
| Electronic copy and one hard copy |
| At initial award |
| 100% Received |
| 5 |
| Turn Around Time |
| One electronic copy |
| Monthly |
| 95% meets established limits |
| 6 |
| Proficiency Testing |
| One electronic copy |
| 90 days prior to the end of contract period |
| 95% meets success rates |
| 7 |
| Antibiogram Report |
| One electronic copy |
| Annually |
| 100% Received |
17. LABORATORY TEST LIST WITH ANNUAL VOLUME AND TAT
| CPT |
| DESCRIPTION |
| Annual Qty |
| TAT in Hrs |
| 86592 |
| RPR [FOLLOW-UP] |
| 1 |
| 24 |
| 86780 |
| Treponema pallidum (Syphilis) Screening Cascade |
| 218 |
| 24 |
| 84075 |
| Alkaline Phosphatase |
| 1 |
| 24 |
| 84100 |
| Phosphorus, Inorganic |
| 4 |
| 24 |
| 84550 |
| Uric Acid, Serum or Plasma |
| 12 |
| 24 |
| 82550 |
| CREATINE KINASE |
| 1 |
| 24 |
| 82310 |
| Calcium, Serum or Plasma |
| 3 |
| 24 |
| 82565 |
| CREATININE WITH GFR |
| 8 |
| 24 |
| 82570 |
| CREATININE, URINE QUANT |
| 1 |
| 24 |
| 84105 |
| PHOSPHORUS, URINE QUANT |
| 1 |
| 24 |
| 84300 |
| SODIUM, URINE QUANT |
| 1 |
| 24 |
| 82340 |
| CALCIUM, URINE QUANT |
| 10 |
| 24 |
| 82043 82570 |
| MICROALBUMIN, URINE (RANDOM) |
| 80 |
| 24 |
| 84156 |
| Protein, Urine [Random] |
| 1 |
| 24 |
| 87591 |
| Neisseria Gonorrhea RNA |
| 1 |
| 24 |
| 87491 |
| Chlamydia Aptima |
| 3 |
| 24 |
| 87491 87591 |
| Neisseria Gonorrhea and Chlamydia RNA |
| 175 |
| 24 |
| 82570 84156 |
| Protein / Creatinine Ratio, Urine |
| 2 |
| 48 |
| 87480 87510 87660 |
| Vaginitis Panel - DNA Probe |
| 11 |
| 24 |
| 81241 |
| Factor V Leiden |
| 5 |
| 48 |
| 81240 |
| PT Gene Mutation |
| 2 |
| 48 |
| 82340 82570 |
| Calcium/Creatinine, Urine Quant |
| 1 |
| 24 |
| 86376 86800 |
| Thyroid Autoantibody Group |
| 10 |
| 24 |
| 82784x3 |
| Immunoglobulin Panel (IgA, IgG, IgM) |
| 10 |
| 48 |
| 82728 83540 84466 |
| Iron Deficiency Panel |
| 7 |
| 24 |
| 86706 |
| Hepatitis B Virus Surface Antibody Quant [Second Choice] |
| 1 |
| 48 |
| 80400 82533 |
| COSYNTROPIN PANEL |
| 1 |
| 48 |
| 86704 86706 86803 87340 |
| Hepatitis B+C Panel |
| 1 |
| 48 |
| 84439 84443 |
| Free T4 w/ TSH |
| 7 |
| 24 |
| 80069 |
| RENAL FUNCTION PANEL |
| 5 |
| 24 |
| 80048 |
| BASIC METABOLIC PANEL |
| 54 |
| 24 |
| 80053 |
| COMPREHENSIVE METABOLIC PANEL |
| 233 |
| 24 |
| 80076 |
| HEPATIC FUNCTION PANEL |
| 3 |
| 24 |
| 81050 82570 |
| Microalbumin / Creatinine, 24 Hour |
| 1 |
| 24 |
| 80074 |
| Hepatitis, Acute |
| 1 |
| 24 |
| 82150 |
| Amylase, Serum or Plasma |
| 2 |
| 24 |
| 82140 |
| Ammonia, Plasma |
| 1 |
| 24 |
| 83540 84466 |
| Iron and Total Iron Binding |
| 2 |
| 24 |
| 83690 |
| Lipase, Serum or Plasma |
| 96 |
| 24 |
| 83036 |
| Hemoglobin A1C Panel |
| 182 |
| 24 |
| 83930 |
| Osmolality, Serum or Plasma |
| 4 |
| 24 |
| 83935 |
| Osmolality, Urine |
| 3 |
| 24 |
| 82533 |
| Cortisol (AM) |
| 17 |
| 24 |
| 84443 |
| TSH, 3rd Generation |
| 180 |
| 24 |
| 83605 |
| Lactic Acid, Plasma |
| 2 |
| 24 |
| 80320 |
| Alcohol, Urine |
| 4 |
| 24 |
| 80176 80329 |
| Acetaminophen |
| 1 |
| 24 |
| 87340 |
| Hepatitis B Surface Antigen |
| 5 |
| 48 |
| 86706 |
| Hepatitis B Virus Surface Antibody, Post-Vaccination |
| 9 |
| 48 |
| 84703 |
| HCG, Qual Serum |
| 2 |
| 24 |
| 84702 |
| HCG, Quant Serum |
| 8 |
| 24 |
| 82607 82746 |
| Vitamin B12 and Folate |
| 1 |
| 24 |
| 84153 |
| PSA, Ultrasensitive |
| 62 |
| 24 |
| 83001 83002 |
| FSH and LH |
| 1 |
| 24 |
| 84443 |
| TSH w/Free T4 Reflex |
| 1 |
| 24 |
| 83525 |
| Insulin, Fasting |
| 1 |
| 24 |
| 84153 84154 |
| PSA, Ultrasensitive Total and Free |
| 2 |
| 24 |
| 82785 |
| Immunoglobulin E |
| 5 |
| 48 |
| G0103 |
| PSA, MC Screening |
| 1 |
| 24 |
| 86803 |
| Hepatitis C Virus Antibody |
| 4 |
| 48 |
| 82103 |
| A-1 Antitrypsin |
| 9 |
| 24 |
| 86038 |
| Anti-Nuclear Antibody |
| 153 |
| 48 |
| 86140 |
| C-Reactive Protein |
| 3 |
| 24 |
| 82784 |
| Immunoglobulin G |
| 7 |
| 48 |
| 82784 |
| Immunoglobulin A |
| 8 |
| 48 |
| 82784 |
| Immunoglobulin M |
| 5 |
| 48 |
| 86618 |
| Lyme Antibody, Total |
| 15 |
| 24 |
| 86255 |
| Mitochondrial Antibody |
| 2 |
| 24 |
| 86308 |
| Mononucleosis Screen |
| 1 |
| 24 |
| 84703 |
| HCG, Qual Urine |
| 1 |
| 24 |
| 86431 |
| Rheumatoid Factor |
| 160 |
| 24 |
| 86255 |
| Smooth Muscle Antibody |
| 7 |
| 24 |
| 86160 |
| Complement Component 3 |
| 2 |
| 24 |
| 86160 |
| Complement Component 4 |
| 2 |
| 24 |
| 86235x2 |
| Sjogren Antibodies |
| 4 |
| 48 |
| 86644 86645 |
| Cytomegalovirus Antibodies, IgG / IgM |
| 9 |
| 24 |
| 84134 |
| Prealbumin, Serum |
| 6 |
| 24 |
| 82375 |
| Carbon Monoxide |
| 1 |
| 24 |
| 83520x2 |
| MPO/PR3 (ANCA) Antibodies |
| 9 |
| 48 |
| 87280 |
| Respiratory Syncytial Virus DFA |
| 1 |
| 24 |
| 87260 |
| Adenovirus [DFA] |
| 1 |
| 24 |
| 87279x3 |
| Parainfluenza Antigens 1,2,3 [DFA] |
| 1 |
| 24 |
| VOLUME (ML) [URINE] |
| 35 |
| 24 |
| 82570 |
| Creatinine, Urine (Random) |
| 3 |
| 24 |
| 86038 |
| Anti-Nuclear Antibody w/Reflex |
| 1 |
| 24 |
| 86708 |
| Hepatitis A Virus Antibody, Total |
| 1 |
| 82731 |
| Fetal Fibronectin |
| 1 |
| 83695 |
| Lipoprotein (a) |
| 1 |
| 24 |
| 86235 |
| dsDNA (Double Stranded DNA) Antibody |
| 3 |
| 24 |
| 82105 |
| AFP Tumor Marker |
| 185 |
| 24 |
| 85303 |
| Protein C, Functional |
| 4 |
| 24 |
| 85306 |
| Protein S, Functional |
| 3 |
| 24 |
| 86317 |
| Rubella Ab, IgG |
| 7 |
| 24 |
| 85240 85245 85246 |
| Von Willebrand Panel |
| 1 |
| 48 |
| 84702 |
| Beta HCG, Tumor |
| 7 |
| 24 |
| 82306 |
| Vitamin D 25-OH |
| 49 |
| 24 |
| 86318 |
| H. pylori, IgG (STAT) |
| 60 |
| 24 |
| 86735 |
| Mumps Antibody, IgG |
| 208 |
| 24 |
| 86765 |
| Rubeola Antibody, IgG |
| 208 |
| 24 |
| 87521 87522 |
| Hepatitis C RNA Quant by PCR |
| 3 |
| 48 |
| 86787 |
| Varicella Zoster Virus Antibodies, IgG |
| 203 |
| 24 |
| 87502 |
| Influenza A/B RNA (Rapid-Molecular) |
| 2 |
| 24 |
| 86803 |
| Hepatitis C Virus Antibody with Reflex |
| 1 |
| 48 |
| 87516 87517 |
| Hepatitis B Virus, Quant by PCR |
| 1 |
| 48 |
| 86695 86696 |
| Herpes Simplex Virus 1 and 2 Antibody, IgG |
| 88 |
| 24 |
| 82172 |
| Apolipoprotein B |
| 2 |
| 24 |
| 83516 |
| Deaminated Gliadin Peptide Antibody, IgA |
| 2 |
| 48 |
| 83516 |
| Deaminated Gliadin Peptide Antibody, IgG |
| 1 |
| 48 |
| 83516 |
| Tissue Transglutaminase Antibody, IgG |
| 3 |
| 48 |
| 86695 |
| Herpes Simplex Virus Type 1, IgG |
| 3 |
| 24 |
| 86696 |
| Herpes Simplex Virus Type 2, IgG |
| 3 |
| 24 |
| 83516 |
| Tissue Transglutaminase Antibody, IgA |
| 4 |
| 48 |
| 86376 |
| Thyroid Peroxidase IgG |
| 5 |
| 48 |
| 86800 |
| Thyroglobulin IgG |
| 1 |
| 24 |
| 87529x2 |
| Herpes Simplex Virus, DNA |
| 9 |
| 48 |
| 87798 |
| Bordetella Pertussis DNA |
| 2 |
| 48 |
| 86788 86789 |
| West Nile Antibody, IgG / IgM |
| 2 |
| 72 |
| 87661 |
| Trichomonas RNA |
| 4 |
| 24 |
| 87491 87591 87661 |
| Neisseria Gonorrhea, Chlamydia, and Trichomonas RNA |
| 15 |
| 24 |
| 87389 |
| HIV 1/2 Antigen and Antibodies, Fourth Generation |
| 7 |
| 24 |
| 86481 |
| T-SPOT, Tuberculosis (TB) |
| 504 |
| 48 |
| 86200 |
| Cyclic Citrullinated Peptide 3 Antibody, IgG (CCP3) |
| 32 |
| 48 |
| 85613 85730 |
| Lupus Screening Panel |
| 6 |
| 24 |
| 85651 |
| Erythrocyte Sedimentation Rate (ESR) |
| 7 |
| 72 |
| 85045 |
| Reticulocyte Count, Automated |
| 2 |
| 24 |
| 87640 87641 |
| Methicillin Resistant Staphylococcus Aureus / Methicillin Susceptible Staphylococcus Aureus (MRSA/MSSA) Screen by PCR |
| 1 |
| 24 |
| 87556 87798 |
| Mycobacterium Tuberculosis Complex and Rifampin Resistance by PCR |
| 5 |
| 48 |
| 87493 |
| Clostridium Difficile Antigen and Toxin B gene by PCR |
| 67 |
| 24 |
| 81001 |
| Urinalysis with C&S if Indicated |
| 215 |
| 24 |
| 85610 |
| Prothrombin Time |
| 597 |
| 24 |
| 85730 |
| Partial Thromboplastin Time |
| 1 |
| 24 |
| 85610 |
| INR INR [YVH ONLY] |
| 4 |
| 24 |
| 85610 |
| INR, FINGERSTICK |
| 18 |
| 24 |
| 85610 |
| PROTIME, FINGERSTICK |
| 49 |
| 24 |
| 85048 |
| Eosinophil Count |
| 1 |
| 24 |
| 86900 86901 |
| ABO Group and RH |
| 13 |
| 24 |
| 87070 |
| Culture, Aerobic without Gram Stain |
| 1 |
| 48 |
| 87077 |
| Culture, Aerobic Identification |
| 3 |
| 24 |
| 87081 |
| Culture, Strep |
| 23 |
| 48 |
| 87070 |
| Definitive Throat Culture |
| 4 |
| 48 |
| 87086 |
| Culture, Urine |
| 1062 |
| 48 |
| 87070 87205 |
| Culture, Aerobic [w/ Gram Stain] |
| 40 |
| 48 |
| 87040 |
| Culture, Blood |
| 4 |
| 48 |
| 87070 87075 87205 |
| Culture, Aerobic / Anaerobic |
| 18 |
| 48 |
| 87045 87046x3 |
| Culture, Stool |
| 47 |
| 48 |
| 87015 87116 87206 |
| Culture, AFB [Non-Blood / Bone Marrow] |
| 13 |
| 48 |
| 87101 |
| Culture - Fungus, Skin |
| 5 |
| 48 |
| 87102 |
| Culture - Fungus, Other Sources |
| 4 |
| 72 |
| 87177 87209 |
| Ova and Parasites |
| 58 |
| 24 |
| 87206 |
| Cryptosporidium, Acid-Fast Bacillus |
| 1 |
| 24 |
| 82705 |
| Fecal Fat Qual |
| 1 |
| 24 |
| 87172 |
| Pinworm Tape Test |
| 3 |
| 48 |
| 87177 |
| Parasite Identification |
| 1 |
| 48 |
| 87329 |
| Giardia Antigen |
| 17 |
| 24 |
| 87328 |
| Cryptosporidium Antigen |
| 15 |
| 48 |
| 84270 |
| Sex Hormone Binding Globulin |
| 4 |
| 48 |
| 84270 84403 |
| Testosterone, Free + Total |
| 4 |
| 24 |
| 82310 83970 |
| Parathyroid Hormone, Intact (PTH) |
| 2 |
| 24 |
| 87210 |
| KOH Prep, Other sources |
| 3 |
| 24 |
| 87220 |
| KOH Prep, Skin, Hair, and Nails |
| 33 |
| 24 |
| 87077 |
| AEROBIC ID, VITEK |
| 559 |
| 24 |
| 87077 |
| AEROBIC ID, OTHER |
| 5 |
| 24 |
| 87186 |
| SUSCEPT, VITEK |
| 508 |
| 24 |
| 80307 82570 |
| Drug Screen, Urine Pain Management |
| 4 |
| 24 |
| 82784 83516x3 |
| Gluten Sensitivity Panel |
| 27 |
| 24 |
| 80361 80365 80362 |
| VA OPIATE PANEL |
| 1883 |
| 24 |
| 80324 |
| Amphetamine, Urine (Confirmation) |
| 33 |
| 24 |
| 80348 |
| Buprenorphine, Urine (Confirmation) |
| 1 |
| 24 |
| 80346 |
| Benzodiazepines, Urine (Confirmation) |
| 4 |
| 24 |
| 80353 |
| Cocaine, Urine (Confirmation) |
| 1 |
| 48 |
| 80321 |
| Ethyl Alcohol, Urine (Confirmation) |
| 502 |
| 24 |
| 80354 |
| Fentanyl, Urine (Confirmation) |
| 15 |
| 24 |
| 80358 |
| Methadone, Urine (Confirmation) |
| 13 |
| 24 |
| 80362 |
| Phencyclidine, Urine (Confirmation) |
| 6 |
| 24 |
| 80362 |
| Naloxone, Urine (Confirmation) |
| 2 |
| 24 |
| 80362 |
| Phencyclidine, Urine (Confirmation) |
| 2 |
| 24 |
| 80349 |
| Cannabinoids, Urine (Confirmation) |
| 3 |
| 24 |
| 80373 |
| Tramadol, Urine (Confirmation) |
| 151 |
| 24 |
| 80359 |
| Ecstasy, Urine (Confirmation) |
| 1 |
| 72 |
| 82570 G0483 |
| Medication Management Expanded Confirmation Panel with TCA |
| 6 |
| 48 |
| 80365 |
| Oxycodone, Urine (Confirmation) |
| 2 |
| 24 |
| 86003 |
| Allergy - Immunocap, Almond [IgE] |
| 1 |
| 24 |
| 86003 |
| Allergy - Immunocap, Cat Dander [IgE] |
| 1 |
| 24 |
| 86003 |
| Allergy - Immunocap, Dog Dander [IgE] |
| 2 |
| 24 |
| 86003x12 |
| Allergy - Immunocap, Adult Food Profile |
| 1 |
| 24 |
| 86003x20 |
| Allergy - Immunocap, Adult Food Panel 20 [IgE] |
| 2 |
| 24 |
| 86003x21 |
| Allergy - Immunocap, NW Region II [IgE] |
| 1 |
| 48 |
| 86003x17 |
| Allergy - Immunocap, Inhalant Panel NW |
| 1 |
| 48 |
| 86003x16 |
| Allergy - Immunocap, NW Region Pollen Panel |
| 2 |
| 48 |
| 86003x7 |
| Allergy - Immunocap, Environmental Panel |
| 1 |
| 24 |
| 86003x22 |
| Allergy - Immunocap, Adult Food Panel 22 |
| 6 |
| 24 |
| 80323 |
| Nicotine, Serum |
| 1 |
| 24 |
| 80180 |
| Mycophenolic Acid and Metabolites |
| 7 |
| 24 |
| 87252 |
| Culture, Viral (Non-Respiratory) |
| 3 |
| 48 |
| 86790 |
| Hepatitis E Virus (HEV) Antibody, IgG |
| 1 |
| 48 |
| 86790 |
| Hepatitis E Virus (HEV) Antibody, IgM |
| 1 |
| 48 |
| 83835 |
| Metanephrines Fractionated, Urine |
| 5 |
| 24 |
| 86255 86671x2 |
| Inflammatory Bowel Panel |
| 2 |
| 24 |
| 83013 |
| H. Pylori-C-Urea, Adult [Breath Test] |
| 1 |
| 24 |
| 86800 |
| Thyroglobulin Panel |
| 9 |
| 24 |
| 82340 82436 82507 83735 83945 83986 84105 84133 84300 84392 84560 |
| Kidney Stone Risk Panel II |
| 2 |
| 24 |
| 87449 |
| Blastomyces dermatitidis Antigen Quantitative by EIA |
| 1 |
| 48 |
| 82634 |
| 11-Deoxycortisol Quantitative, Serum |
| 1 |
| 24 |
| 83497 |
| 5-Hydroxyindoleacetic Acid (HIAA), Urine |
| 3 |
| 48 |
| 83519 |
| Acetylcholine Receptor Binding Antibody |
| 1 |
| 24 |
| 82088 |
| Aldosterone, Serum |
| 2 |
| 48 |
| 82088 |
| Aldosterone, Urine |
| 3 |
| 48 |
| 82103 82104 |
| Alpha-1-Antitrypsin Phenotype |
| 1 |
| 24 |
| 80335 |
| Amitriptyline + Nortriptyline |
| 3 |
| 48 |
| 82164 |
| Angiotensin Converting Enzyme |
| 1 |
| 24 |
| 85300 |
| Antithrombin, Enzymatic (Activity) |
| 4 |
| 48 |
| 85307 |
| APC Resistance |
| 1 |
| 48 |
| 83519 |
| Acetylcholine Receptor Modulating Antibody |
| 1 |
| 24 |
| 82232 |
| Beta-2-Microglobulin, Serum |
| 2 |
| 24 |
| 82330 |
| Calcium, Ionized |
| 15 |
| 24 |
| 82384 |
| Catecholamines, Urine |
| 2 |
| 24 |
| 82495 |
| Chromium, Serum |
| 1 |
| 48 |
| 86316 |
| Chromogranin A |
| 3 |
| 48 |
| 80335 |
| Clomipramine + Metabolite |
| 1 |
| 24 |
| 86635x2 |
| Coccidioides Antibodies, IgG & IgM |
| 1 |
| 48 |
| 86162 |
| Complement, Total |
| 2 |
| 24 |
| 82530 |
| Cortisol, Urinary Free |
| 3 |
| 24 |
| 83519 |
| Acetylcholine Receptor Blocking Antibody |
| 1 |
| 24 |
| 87798 |
| EBV by PCR , Qualitative |
| 1 |
| 24 |
| 82668 |
| Erythropoietin |
| 22 |
| 48 |
| 82671 |
| Estrogens, Serum Fractionated |
| 12 |
| 24 |
| 83516 |
| Glomerular Basement Membrane Antibody, IgG |
| 1 |
| 24 |
| 82175 82300 83655 83825 |
| Heavy Metals Panel, Blood |
| 5 |
| 48 |
| 83021 |
| Hemoglobin S with Reflex |
| 1 |
| 24 |
| 86707 |
| Hepatitis Be Antibody |
| 5 |
| 48 |
| 87350 |
| Hepatitis Be Antigen |
| 12 |
| 48 |
| 86698x2 |
| Histoplasma Antibodies |
| 1 |
| 48 |
| 86694 |
| Herpes Simplex Virus 1 and/or 2 Antibody, IgM |
| 3 |
| 24 |
| 83835 |
| Metanephrines, Plasma |
| 4 |
| 24 |
| 82340 82507 83945 84560 |
| Kidney Stone Risk Panel, Urine |
| 7 |
| 24 |
| 86376 |
| LKM Antibodies, IgG |
| 3 |
| 24 |
| 84143 |
| 17-Hydroxypregnenolone Quantitative |
| 1 |
| 24 |
| 86617x2 |
| Lyme Antibodies, IgG / IgM Immunoblot |
| 1 |
| 24 |
| 83735 |
| Magnesium, Urine |
| 1 |
| 24 |
| 83921 |
| Methylmalonic Acid, Serum or Plasma |
| 18 |
| 24 |
| 86735 |
| Mumps Virus Antibody, IgM |
| 2 |
| 24 |
| 86738x2 |
| Mycoplasma pneumoniae Antibodies, IgG/IgM |
| 1 |
| 48 |
| 80185 80186 |
| Phenytoin, Free and Total |
| 1 |
| 24 |
| 85302 |
| Protein C, Total Antigen |
| 2 |
| 24 |
| 85305 |
| Protein S, Total Antigen |
| 2 |
| 24 |
| 84244 |
| Renin Activity |
| 5 |
| 24 |
| 83519x2 |
| Acetylcholine Receptor Antibody Panel |
| 1 |
| 24 |
| 82365 |
| Stone Analysis |
| 2 |
| 48 |
| 86592 |
| Treponema pallidum (VDRL), Serum |
| 1 |
| 24 |
| 84585 |
| Vanillylmandelic Acid |
| 1 |
| 24 |
| 84588 |
| Antidiuretic Hormone |
| 1 |
| 24 |
| 81256 |
| Hemochromatosis |
| 11 |
| 24 |
| 86692 |
| Hepatitis Delta Antibody |
| 2 |
| 24 |
| 86606 |
| Aspergillus Antibody by Immunodiffusion |
| 1 |
| 24 |
| 87338 |
| Helicobacter pylori Antigen, Stool |
| 17 |
| 24 |
| 82088 84244 |
| Aldosterone/Renin Activity Ratio |
| 1 |
| 48 |
| 80150 |
| Amikacin, Trough Level |
| 1 |
| 24 |
| 86787 |
| Varicella Zoster Virus Antibody, IgM |
| 1 |
| 48 |
| 80177 |
| Levetiracetam |
| 29 |
| 24 |
| 86341 |
| Glutamic Acid Decarboxylase Antibody |
| 12 |
| 24 |
| 86340 |
| Intrinsic Factor Blocking Antibody |
| 2 |
| 48 |
| 84445 |
| Thyroid Stimulating Immunoglobulin |
| 3 |
| 24 |
| 80323 |
| Nicotine, Urine |
| 7 |
| 24 |
| 86317x2 |
| Diphtheria + Tetanus Antibodies, IgG |
| 1 |
| 48 |
| 84075 84080 |
| Alkaline Phosphatase Isoenzymes |
| 10 |
| 24 |
| 86622 |
| Brucella Antibody |
| 1 |
| 48 |
| 83883x2 |
| Kappa-Lambda Free Light Chains, Quantitative |
| 18 |
| 48 |
| 86317x14 |
| Streptococcus pneumoniae Antibodies, IgG (14 Serotypes) |
| 1 |
| 24 |
| 86359 86360 |
| CD4/CD8 Panel |
| 15 |
| 48 |
| 84238 |
| Soluable Transferrin Receptor |
| 1 |
| 24 |
| 80061 83704 |
| NMR, Lipoprofile |
| 1 |
| 24 |
| 80349 |
| Marijuana, Serum [Confirmation] |
| 3 |
| 48 |
| 80353 |
| Cocaine, Serum [Confirmation] |
| 1 |
| 48 |
| 88184 |
| Leukemia/Lymphoma Phenotyping [Flow Cytometry] |
| 2 |
| 48 |
| 83498 |
| 17-Hydroxyprogesterone |
| 2 |
| 24 |
| 81381 |
| HLA-B*5701 Associated Variant Genotyping |
| 1 |
| 48 |
| 86255 |
| Striated Muscle Antibodies, IgG with Reflex to Titer |
| 1 |
| 24 |
| 82657 |
| Thiopurine Methyltransferase, RBC Activity |
| 1 |
| 72 |
| 82787 |
| IgG Subclass 4 |
| 1 |
| 24 |
| 86256 |
| Endomysial Antibody, IgA |
| 2 |
| 48 |
| 83825 |
| Mercury, Blood |
| 1 |
| 24 |
| 80361 |
| Opiates, Serum [Confirmation] |
| 1 |
| 24 |
| 80307 |
| Drugs of Abuse, Serum (Medical) |
| 6 |
| 24 |
| 80342 |
| Risperidone and Metabolite |
| 1 |
| 24 |
| 86787x2 |
| Varicella Zoster Virus Antibodies, IgG & IgM |
| 6 |
| 48 |
| 83018 |
| Cobalt, Serum or Plasma |
| 1 |
| 24 |
| 81270 |
| JAK2 Gene, V617F Mutation, Qualitative |
| 28 |
| 48 |
| THYROGLOBULIN, SERUM OR PLASMA |
| 2 |
| 24 |
| Microalbumin, Urine Quant (Random) |
| 2 |
| 24 |
| 84165 |
| Protein electrophoretic fract serum |
| 1 |
| 24 |
| 87046 |
| CUL BACT STL AERC ADDL PATHOGENS&ID EA |
| 3 |
| 48 |
| 87209 |
| Smear, Primary Source Interp; Complex stain |
| 1 |
| 72 |
| 87275 |
| Influenza B Virus |
| 1 |
| 48 |
| 87276 |
| Influenza A Virus |
| 1 |
| 48 |
| truSwab Vaginitis Panel |
| 1 |
| 48 |
| 82570 |
| CREATININE, URINE |
| 15 |
| 24 |
| 86331 |
| Immunodiffusion |
| 7 |
| 24 |
| 86606 |
| Aspergillus Antibody |
| 5 |
| 24 |
| 80299 |
| ADALIMIMAB ACT W/REFLEX TO AB |
| 2 |
| 48 |
| 80332 |
| FLUOXETINE & METABOLITE QUANT |
| 1 |
| 24 |
| 80367 |
| PROPOXYPHENE, CONF |
| 1 |
| 48 |
| 80367 |
| PROPOXYPHENE & METABOLITE URINE QUANT |
| 4 |
| 48 |
| 81403 |
| JAK2 EXON 12 MUTATION ANALYSIS BY PCR |
| 1 |
| 48 |
| 81539 |
| PROSTATE SPECIFIC KALLIKREIN 4 KSCORE |
| 3 |
| 48 |
| 81539 |
| PROSTATE SPECIFIC KALLIKREIN 4KSCORE |
| 11 |
| 48 |
| 82595 |
| CRYOGLOBULIN, QUAL w/REFLEX TO QUANT IgA,IgG,IgM |
| 2 |
| 48 |
| 82784 |
| MONOCLONAL PROTEIN DETECT PANEL |
| 3 |
| 48 |
| 84156 |
| KAPPA LAMBDA FREE LIGHT CHAINS QUAL |
| 1 |
| 48 |
| 84160 |
| MONOCLONAL PROTEIN DETECTION PANEL |
| 1 |
| 48 |
| 84165 |
| MONOCLONAL PROTEIN DETECTION PANEL |
| 1 |
| 48 |
| 84270 |
| TESTOSTERONE BIO SHBG |
| 1 |
| 48 |
| 84403 |
| TESTOSTERONE BIO SHBG |
| 1 |
| 48 |
| 85306 |
| PROTEIN S FREE ANTIGEN |
| 1 |
| 24 |
| 85520 |
| APIXABAN ANTIXA |
| 1 |
| 48 |
| 86256 |
| DOUBLE STRANDED DNA dsDNA AB IgG BY IFA |
| 1 |
| 48 |
| 86334 |
| MONOCLONAL PROTEIN DETECTION PANEL |
| 1 |
| 48 |
| 86335 |
| KAPPA LAMBDA FREE LIGHT CHAINS QUAL |
| 1 |
| 48 |
| 87081 |
| FLUOROQUINOLONE RESISTANT ORG CULTURE |
| 1 |
| 48 |
| 87253 |
| VIRUS IDENTIFICATION (BILLED) |
| 1 |
| 24 |
| 87385 |
| HISTOPLASMA AG URINE |
| 1 |
| 24 |
| 87529 |
| HSV 1&2 AB IgG CSF BY PCR |
| 25 |
| 24 |
| 87529 |
| HERPES SIMPLEX PCR ARUP |
| 28 |
| 72 |
| 87798 |
| MALARIA DETECTION AND SPECIATION QUAL |
| 1 |
| 48 |
| 88184 |
| TECHNICAL LEUK/LYMPH PHENO, 20 MARKERS |
| 1 |
| 48 |
| 88184 |
| TECHNICAL LEUK/LYMPH PHENO, 21 MARKERS |
| 1 |
| 48 |
| 88185 |
| TECHNICAL LEUK/LYMPH PHENO, 20 MARKERS |
| 19 |
| 48 |
| 88185 |
| TECHNICAL LEUK/LYMPH PHENO, 21 MARKERS |
| 20 |
| 48 |
| 88189 |
| PROF LEUK/LYMPH PHENO 16 OR MORE MARKERS |
| 2 |
| 48 |
See attached document: P09 Revised Test listing with quantities and TAT.